Get started
Author

Timothy Bancroft

Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients
2013 · Sumeet Panjabi, Michael Lacey, et al. · Journal of the American Society of Hypertension · 60
The Identification and Cost of Acute Chronic Obstructive Pulmonary Disease Exacerbations in a United States Population Healthcare Claims Database
2020 · Richard H. Stanford, Nicole M. Engel-Nitz, et al. · COPD Journal of Chronic Obstructive Pulmonary Disease · 19
Adverse Clinical Outcomes in Patients With Crohn’s Disease Receiving Different Sequences of First- and Second-line Biologic Treatments: Findings From Rotary
2022 · Noa Cleveland, Benjamin Chastek, et al. · Inflammatory Bowel Diseases · 1
PDF
Adverse Clinical Outcomes in Patients With Ulcerative Colitis Receiving Different Sequences of First- and Second-line Biologic Treatments: Findings From Rotary
2022 · Noa Cleveland, Benjamin Chastek, et al. · Inflammatory Bowel Diseases · 1
PDF
Real-world time to treatment initiation among NGS tested versus untested patients with metastatic lung or colorectal cancer.
2025 · Gieira S. Jones, Clementine Adeyemi, et al. · JCO Oncology Practice
EE365 Real-World Healthcare Resource Utilization and Economic Burden Associated With Progressive Pulmonary Fibrosis in Commercially Insured and Medicare Advantage Populations in the United States
2025 · Joseph S. Yang, Bonnie Bui, et al. · Value in Health
Adverse Clinical Outcomes in Patients With Crohn’s Disease Receiving Different Sequences of First- and Second-line Biologic Treatments: Findings From Rotary
2022 · Noa Cleveland, Benjamin Chastek, et al. · Gastroenterology
Adverse Clinical Outcomes in Patients With Ulcerative Colitis Receiving Different Sequences of First- and Second-line Biologic Treatments: Findings From Rotary
2022 · Noa Cleveland, Benjamin Chastek, et al. · Gastroenterology
S921 Persistence of First and Second Lines of Biologic Treatment Across Different Treatment Sequences in Patients With Inflammatory Bowel Disease Receiving at Least Two Biologics: Findings from ROTARY-1
2021 · Noa Krugliak Cleveland, Benjamin Chastek, et al. · The American Journal of Gastroenterology
What Is the Cost of Disease Progression Among Patients with Indolent or Aggressive Non-Hodgkin Lymphoma (NHL)?
2016 · Nicole Engel-Nitz, Stacey Dacosta Byfield, et al. · Blood
Understanding disease progression and treatment patterns in metastatic breast, colorectal, and lung cancer: Implications for evaluating value and quality of care.
2016 · Nicole M. Engel-Nitz, Stacey DaCosta Byfield, et al. · Journal of Clinical Oncology
Differences in Patients with Progressive Versus Non-Progressive AML, CLL, or NHL: Implications for Proposed Bundled Payment Strategies
2015 · Stacey Dacosta Byfield, Nicole Engel-Nitz, et al. · Blood
Works count: 12
Citation count: 81
H-index: 2
I10-index: 2
Year
Topic
Type